[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"customer-session":3,"post:ghk-cu-peptide-concentration-routes-and-research-reference-guide":5},{"loggedIn":4},false,{"id":6,"slug":7,"title":8,"content":9,"excerpt":10,"path":11,"modified":12,"featuredImage":13,"seo":17,"date":20,"author":18,"categories":21,"readingMinutes":28},41717,"ghk-cu-peptide-concentration-routes-and-research-reference-guide","GHK-Cu Peptide: Concentration, Routes, and Research Reference Guide","\u003Cp>\u003Cspan style=\"font-weight: 400;\">By \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fauthor\u002Fclarkjones\u002F\">\u003Cspan style=\"font-weight: 400;\">Clark Jones, PhD\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">, Velora Research \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297)). Last reviewed 2026-05-28.\u003C\u002Fspan>\u003C\u002Fi>\u003C\u002Fp>\n\u003Cp>\u003Cb>Quick answer:\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> GHK is a short tripeptide that forms a high-affinity complex with copper(II), producing the GHK-Cu complex most commonly investigate in research. In the lab it ships as a blue-tinted lyophilized powder, and that color is exactly what it should be. A common research format is a 100 mg vial reconstituted in 5 mL of bacteriostatic water, giving you 20 mg\u002FmL of GHK-Cu, which corresponds to roughly 51 mM. Every Velora GHK-Cu batch is third-party COA-verified, including quantitative verification of copper content, which is an important quality attribute of the peptide-copper complex.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Research use only: what this article is, and what it isn’t\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">This article is a benchwork reference for researchers handling GHK-Cu in vitro or in preclinical models. It is not medical advice. It is not a dosing protocol for any human or veterinary subject. GHK-Cu is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other national regulator as a drug for any indication.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The 100 mg lyophilized GHK-Cu Velora supplies is sold strictly for laboratory research use, not for human consumption, veterinary use, or in vivo use in any species. The concentration tables and route discussions below are drawn from the published preclinical and in-vitro literature on GHK and GHK-Cu. They are reported here for research orientation, not as a treatment protocol.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Researchers are responsible for compliance with applicable law, including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331, § 355, § 360bbb-3), and institutional review requirements where applicable.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>What GHK-Cu actually is\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">GHK is a tripeptide with the sequence glycyl-L-histidyl-L-lysine, originally identified in human plasma in the 1970s. It binds copper(II) ions with high affinity, and the copper-bound form (GHK-Cu) is the one most often studied in mechanistic research. The molecular weight of GHK alone is approximately 340 daltons; the copper-bound complex sits at roughly 398 daltons (Velora product-page value; literature reports approximately 404 Da) (Velora product-page value; peer-reviewed literature reports approximately 404 Da for the copper-bound complex), depending on the counter-ion and the hydration state.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Native plasma concentrations of GHK have been reported to decline with age, and that observation is part of why the molecule has been studied across decades in skin, hair-follicle, and connective-tissue research models. The deepest body of mechanistic work on GHK-Cu has come from Loren Pickart and collaborators, who have published extensively on its biology across more than four decades (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcosmetics2030236\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Pickart et al., 2015\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">) \u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">In preclinical research, GHK-Cu has been associated with effects on collagen and glycosaminoglycan synthesis in dermal fibroblast models, on hair-follicle morphology in rodent and ex-vivo skin studies, and on expression of genes involved in tissue remodeling. The proposed mechanism most often cited involves copper transport, modulation of growth-factor signaling, and effects on the extracellular matrix.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">A note on what GHK-Cu is not: the human clinical evidence base, particularly outside topical cosmetic studies, is thin. Most of the supporting literature is in vitro, ex vivo, or in animal models. That distinction matters for any methods section.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>What the preclinical research has shown\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The strongest line of GHK-Cu evidence sits in dermal and connective-tissue models. In cultured human fibroblasts and ex-vivo skin systems, GHK-Cu exposure has been associated with increased synthesis of type I collagen, elastin, and proteoglycans, and with increased expression of metalloproteinases involved in matrix turnover. The Pickart group has published gene-expression work in cultured fibroblasts reporting changes across several hundred genes after GHK-Cu exposure, with enrichment in tissue-remodeling and DNA-repair pathways (\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F3169264\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">F. Maquart et al., 1988\u003C\u002Fspan> \u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">)\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The hair-follicle literature is somewhat smaller but consistent in direction, with work in rodent and ex-vivo human follicle systems describing GHK-Cu-associated changes in follicle morphology and dermal papilla cell behavior. As with the skin work, the framing in published reviews remains observational with respect to mechanism, and most authors note that the in vivo translation outside of topical and injected animal-model contexts is not fully characterized.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">If you are designing a study, the takeaway is that the strongest signal is in skin and connective-tissue models, the supporting literature concentrates around the Pickart group’s body of work, and effects outside those model systems should be treated as more provisional.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Concentration reference for a 100 mg vial\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The chemistry of GHK-Cu is forgiving for reconstitution: it dissolves readily in bacteriostatic water, and the characteristic blue color of the solution is a quick visual confirmation that you are handling intact peptide-copper complex.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cb>Vial size\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>BAC water volume\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Stock concentration (mg\u002FmL)\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Molar concentration (mM)\u003C\u002Fb>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">100 mg\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2.5 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">40\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~100\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">100 mg\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">5.0 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">20\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~51\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">100 mg\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">10.0 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">10\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~26\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">50 mg\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2.5 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">20\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~51\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">50 mg\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">5.0 mL\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">10\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~26\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Molar values assume an approximate molecular weight of 398 Da for the copper-bound complex. Working concentrations for cell-based assays typically sit in the nanomolar to low-micromolar range, which means the stock will need substantial serial dilution in your assay buffer. A 20 mg\u002FmL stock (~51 mM) at a 1:10,000 dilution lands at approximately 5.1 µM.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">For the reconstitution itself, use the standard slow-stream technique against the inner glass wall of the vial, swirl gently for 30 to 60 seconds, and do not shake. Label the vial with the date, the gravimetric concentration in mg\u002FmL, and the molar concentration in mM. Note the visible blue color of the working stock; loss of color, or unexpected changes in solution appearance may warrant additional analytical verification. \u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Routes used in published research\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">GHK-Cu has been studied across multiple routes in preclinical work. In rodent and ex-vivo skin studies, topical application is the most common route in the dermal and hair-follicle literature; the relatively low molecular weight of the complex makes it a reasonable candidate for cutaneous delivery research. In other rodent work, subcutaneous administration has been used, particularly for systemic-effect studies. In-vitro work on fibroblasts and cultured tissue uses direct exposure in growth medium at controlled molar concentrations.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Each of these is a research-design choice in an animal or cell-culture system. None of them is a translation to human or veterinary use, and the Velora product is not sold for any of those purposes.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Storage and the light-sensitivity question\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Storage is where GHK-Cu specifically can quietly degrade if you treat it like a generic peptide.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ctable>\n\u003Cthead>\n\u003Ctr>\n\u003Cth>\u003Cb>State\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Temperature\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Light\u003C\u002Fb>\u003C\u002Fth>\n\u003Cth>\u003Cb>Stability window\u003C\u002Fb>\u003C\u002Fth>\n\u003C\u002Ftr>\n\u003C\u002Fthead>\n\u003Ctbody>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Lyophilized (sealed vial)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">-20°C\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Protect from light\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">24+ months from manufacture date (common lab-practice window; Velora has not published stability studies)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Lyophilized (sealed vial)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2 to 8°C\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Protect from light\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~3 months\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Reconstituted in BAC water\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2 to 8°C\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Protect from light, amber vial preferred\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~28 to 30 days (common current practice in other laboratories)\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003Ctr>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Reconstituted in sterile water\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">2 to 8°C\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">Protect from light\u003C\u002Fspan>\u003C\u002Ftd>\n\u003Ctd>\u003Cspan style=\"font-weight: 400;\">~7 days, single-use preferred\u003C\u002Fspan>\u003C\u002Ftd>\n\u003C\u002Ftr>\n\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003Cp> \u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Two practical points. First, the copper ion is photochemically active, so prolonged exposure to UV or visible light can drive degradation of the GHK-Cu complex; an amber vial or a foil wrap is the easy fix. Second, do not freeze the reconstituted stock. Freeze-thaw cycles may alter peptide integrity and metal-complex stability.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">“GHK-Cu is one of those peptides where the COA tells you whether you actually have what the label says. Identity by mass spec is straightforward, but copper content needs to be quantified too, and a clean batch will have both. If the COA only confirms identity of the peptide without quantifying the copper, you don’t yet know what you’re studying.”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Clark Jones, PhD, Velora Research\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Working with verified GHK-Cu\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">Velora’s \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct\u002Fghk-cu-100mg\u002F\">\u003Cspan style=\"font-weight: 400;\">GHK-Cu 100 mg\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> ships with a third-party Certificate of Analysis. The COA covers identity by mass spec, purity by HPLC at ≥99%, water content by Karl Fischer, endotoxin by LAL, and copper content quantification for the peptide-copper complex. Each batch is independently traceable. The same release protocol applies across the \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fproduct-category\u002Fpeptides\u002F\">\u003Cspan style=\"font-weight: 400;\">research peptide catalog\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\">, and \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fveloraresearch.com\u002Fabout-us\u002F\">\u003Cspan style=\"font-weight: 400;\">Velora’s quality and testing process\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan style=\"font-weight: 400;\"> is documented end to end.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan style=\"font-weight: 400;\">The reason this matters for GHK-Cu specifically: the biology that has been characterized in preclinical research depends on the copper-bound form. A vial that confirms peptide identity but says nothing about copper content is not the same product the published literature is built on.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Frequently asked questions\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cp>\u003Cb>How much GHK-Cu should I inject daily?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> That question is outside the scope of this article. GHK-Cu is sold by Velora for laboratory research use only, not for injection into any human or veterinary subject. Concentrations reported in published preclinical animal studies vary widely by model, route, and endpoint, and they are not dosing recommendations.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>What is the molecular weight of GHK-Cu?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> The GHK tripeptide alone is approximately 340 daltons. The copper(II)-bound complex GHK-Cu sits at roughly 398 daltons, depending on counter-ion and hydration. Use the complex weight when calculating molar concentrations from a gravimetric stock of GHK-Cu.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>Why is GHK-Cu blue?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> The blue color comes from the d-d electron transitions of the bound copper(II) ion. Intact GHK-Cu in solution presents as a clear blue. Loss of color can indicate dissociation of the complex.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cb>Is GHK-Cu FDA-approved for any use?\u003C\u002Fb>\u003Cspan style=\"font-weight: 400;\"> No. GHK-Cu is not approved by the FDA or any other national regulator as a drug for any indication. It appears in some cosmetic products at low concentrations regulated under cosmetic-ingredient frameworks; that regulatory context is distinct from drug approval.\u003C\u002Fspan>\u003C\u002Fp>\n\u003Ch2>\u003Cb>Sources and further reading\u003C\u002Fb>\u003C\u002Fh2>\n\u003Cul>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">International Journal of Molecular Sciences\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2018. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.mdpi.com\u002F1422-0067\u002F19\u002F7\u002F1987\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">Full text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cb>Maquart, F. X., Pickart, L., Laurent, M., Gillery, P., Monboisse, J. C., & Borel, J. P. (1988).\u003C\u002Fb> \u003Ci>\u003Cspan style=\"font-weight: 400;\">Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\"> FEBS Letters, 238(2), 343-346.\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F3169264\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\"> Full Text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cb>Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015).\u003C\u002Fb> \u003Ci>\u003Cspan style=\"font-weight: 400;\">GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes.\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\"> Cosmetics, 2(3), 236-247.\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcosmetics2030236\" target=\"_blank\" rel=\"noopener\"> \u003Cspan style=\"font-weight: 400;\">Full Text\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli style=\"font-weight: 400;\" aria-level=\"1\">\u003Cspan style=\"font-weight: 400;\">Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: Resetting the Human Genome to Health. BioMed Research International. 2014;2014:151479. \u003C\u002Fspan>\u003Ci>\u003Cspan style=\"font-weight: 400;\">Biological Research\u003C\u002Fspan>\u003C\u002Fi>\u003Cspan style=\"font-weight: 400;\">. 2017. \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC4178333\u002F\" target=\"_blank\" rel=\"noopener\">\u003Cspan style=\"font-weight: 400;\">PMC\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n","By Clark Jones, PhD, Velora Research Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-0005-9356-0297)). Last reviewed 2026-05-28.…","\u002Fblogs\u002Fghk-cu-peptide-concentration-routes-and-research-reference-guide","2026-07-14T17:25:39",{"src":14,"alt":8,"width":15,"height":16},"https:\u002F\u002Fveloraresearch.com\u002Fwp-content\u002Fuploads\u002F2026\u002F07\u002FGHK-Cu-Peptide-Concentration-Routes-and-Research-Reference-Guide.jpeg",1376,768,{"title":18,"description":19,"canonical":18,"ogTitle":18,"ogDescription":19,"ogImage":14,"robots":18},null,"By Clark Jones, PhD, Velora Research Written and reviewed for scientific accuracy by Clark Jones, PhD ([ORCID 0009-0005-9356-0297](https:\u002F\u002Forcid.org\u002F0009-000…","2026-07-14T17:24:58",[22,25],{"name":23,"slug":24},"Blogs","blogs",{"name":26,"slug":27},"Research & Education","research-education",7]